Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms

Leukemia · Published 2026-07-13 · DOI 10.1038/s41375-026-03044-8

Authors (17)

Anna B. Halpern, Megan Othus, Mary-Elizabeth M. Percival, Cristina Ghiuzeli, Jacob S. Appelbaum, Paul C. Hendrie, Ryan D. Cassaday, Max Smith, Kathryn Russell, Bart L. Scott, Jason P. Cooper, Joshua R. Veatch, Siobán B. Keel, Vivian G. Oehler, Erik L. Kimble, Raya Mawad, Roland B. Walter

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Halpern, A., Othus, M., Percival, M., et al. (2026). Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms. Leukemia. https://doi.org/10.1038/s41375-026-03044-8

Related articles